| Autor: |
Yu-Ting Ma, Yan Li, Li Yan, Fang Hua, Dong-Guan Wang, Guo-Ying Xu, Hong-Lan Yang, Ying-Jie Xue, Ye-Jun Qin, Dan Sha, Hao Ning, Miao-Qing Zhao, Zhi-Gang Yao |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Pathology and Oncology Research, Vol 28 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1532-2807 |
| DOI: |
10.3389/pore.2022.1610638 |
| Popis: |
Immune checkpoint inhibitors (ICIs) have shown encouraging outcomes against Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer with mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H). However, there is as yet no clarity on the safety and efficacy of immunotherapy combined with chemotherapy in LS-associated urothelial carcinoma (UC). Here, we report a patient with recurrent and metastatic LS-associated UC who achieved sustained response to programmed death protein 1 (PD-1) inhibitor combined with chemotherapy over 31 months, during which the side effects of immunotherapy could be controlled and managed. Our findings indicate that the dMMR/MSI status and PD-1 expression in UC may have potential predictive value for the response to PD-1-targeted immunotherapy. Our case supports the inclusion of such combination and/or monotherapy for UC in clinical studies and using dMMR/MSI status and PD-1 expression as potential predictive biomarkers for assessment of the therapeutic response. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
